Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

omestic) and 1-617-213-8852 (international) prior to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, June 26, 2008, at 12:30 PM ET and will be accessible until Thursday, July 3, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 27175887.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through July 26, 2008.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia for which Vanda submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2007. The FDA accepted Vanda's iloperidone NDA for filing in November 2007 and Vanda expects a decision from the FDA on or about July 27, 2008. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Cautionary Note Regarding Forward-Looking Sta
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...., Nov. 26 Children who...gnificantly increased risk of developing mental il... a Mayo Clinic study published this month in Pedi...emy of Pediatrics. , , The retrospective st...ith strabismus (misaligned eyes) and compared them...
(Date:11/26/2008)...to 406 Subjects , , FRANKLIN, Mass., Nov. 2...Bulletin Board: PLCSF) announced today that it has...g Administration (FDA) for its U.S. pivotal trial ...uard System(TM) and associated therapy in the pre... , The FDA also approved PLC,s request to exp...
(Date:11/25/2008)..., Nov. 25 Kleinert Kutz...ormed the fifth U.S. hand transplant on Messina, N...le,s Jewish Hospital Hand Care Center on Monday, N... noon and was completed shortly after 9 p.m. in a ....newscom.com/cgi-bin/prnh/20081125/DC48555-a ) , ...
(Date:11/25/2008)...ISCO, Calif., Nov. 25 Proteolix, I... novel therapeutics that target,protein degradati...ay,announced that data from two ongoing Phase 2 c... will be presented at the upcoming 50th Annual Mee... Carfilzomib is the first in a new class,of spec...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 1Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 9Pre Workout Stretching Wont Prevent Sore Muscles 4020 1Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 1Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 2Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 3Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 4
(Date:12/1/2008)...alker Chooses Two Tampa Beneficiaries for Par and ...AMPA, Fla., Dec. 1 The ...rity of Tampa Bay, Inc. and the Judeo Christian He...he 2009 Par and Poker Celebrity Challenge for Char..., , "It is only appropriate that events like...
(Date:12/1/2008)...the sunlight-derived nutrient tied to increased ca...HealthDay News) -- A lack of vitamin D, which is ...elps boost the risk of heart attacks and strokes, ...of studies linking increased cardiovascular risk w...efe, director of preventive cardiology at the Mid ...
(Date:12/1/2008)..., Dec. 1, 2008 The Arthritis Foundation announces...or research in arthritis. The recipients, Dr. Gera...Physicians and Dr. Michel Nussenzweig of Rockefell...ed research advancements in the cure and control o...zed for his research in the development and functi...
(Date:12/1/2008)... Va., Dec. 1 The Food A...d Julia E. Bradsher, Ph.D., as its new CEO, replac..., , Dr. Bradsher brings to FAAN extensive kn...l allergic reaction. For the past six years, as Se...team and strategic planning for all Dey Pharmaceut...
Breaking Medicine News(10 mins):Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Vitamin D Vital for the Heart 2Health News:Vitamin D Vital for the Heart 3Health News:FAAN Names New CEO 2
... more than 57,000 children found that greater the ...ng poor or having a single mother who is a high sc...g sick, immaterial of race or health insurance cov...ved for long that growing up in physically or ment...
... industry a panel comprising European experts reco...a be approved for sales// in the European Union. T...f. The action of the pill Acomplia (rimonabant) i...t obesity. People on the pill eat less because the...
...ce for Wales published, figures for rates of serio...g MRSA. This step is taken to assure// the public ...h officials to protect the public. John Wardell, ...tion after a hip replacement operation at Abergele...
...to be a common problem with the Middle-aged and ol.... But now, Dr. Najah S. Musacchio, a fellow at Chi...p further in finding out if this problem could hav...er and understand, Musacchio and fellow researcher...
Other Medicine News:Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 2Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 3
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
Medicine Products: